Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
Author(s) -
Courtney L. Kraus,
Susan M. Culican
Publication year - 2011
Publication title -
international journal of rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.8
H-Index - 33
eISSN - 1687-9279
pISSN - 1687-9260
DOI - 10.1155/2012/203819
Subject(s) - medicine , rheumatic disease , disease , intensive care medicine , biologic agents , dermatology , pathology
Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated with rheumatic conditions may present with a wide range of signs and symptoms. This coexisting pathology should not be overlooked and should be considered a reason for initiation or continuation of biologic therapy. Additionally, many of the ocular manifestations of rheumatic disease respond preferentially to specific targeting molecules. This paper summarizes the available studies on the use, efficacy, and safety of biologic agents in the treatment of ocular manifestations of rheumatic disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom